Skip to main content
. 2023 Jun 20;14:1163432. doi: 10.3389/fphar.2023.1163432

TABLE 1.

Overall Response Rate of 60 mg cibisatamab monotherapy, 1200 mg atezolizumab monotherapy and their combination therapy.

Treatment Simulated ORR (%) 95% CI Clinical ORR References
Cibisatamab 8.2 0%–22.6% 6% Tabernero et al. (2017)
Atezolizumab 3.4 0%–12.9% 2% (IMblaze370 trial) Eng et al. (2019)
Combination Therapy 11.1 0%–28% 12% Tabernero et al. (2017)